Appearance
🎉 your ETH🥳
"Seriguda is a village and panchayat in Rangareddy district, Telangana TS, India. It comes under Ibrahimpatnam mandal. It is 27 km away from Hyderabad city. The Outer Ring Road, Hyderabad is 7 km from the village. Rajiv Gandhi International Airport is 40 km away. References Villages in Ranga Reddy district "
"Tumstatin is a protein fragment cleaved from collagen that serves as both an antiangiogenic and proapoptotic agent. It has similar function to canstatin, endostatin, restin, and arresten, which also affect angiogenesis.http://www.copewithcytokines.de/cope.cgi?key=Tumstatin Angiogenesis is the growth of new blood vessels from pre-existing blood vessels, and is important in tumor growth and metastasis. Angiogenesis is stimulated by many growth factors, the most prevalent of which is vascular endothelial growth factor (VEGF). Structure and Function Tumstatin is a 28 kDa fragment cleaved from collagen type IV There are two subsegments of the peptide that are active; T3 peptide and T7 peptide.http://www.phoenixpeptide.com/catalog/pnxfoget.php?id=pnxnews_000000444&title;=Compound∑=Function. The structure is very similar to that of endostatin, which is cleaved from collagen XVIII. The two proteins share 14% amino acid identity, making them very similar in structure. It has been proven to inhibit many types of cells, including bovine endothelial cells, HeLa cells, endothelial cells, and Human umbilical vein endothelial cells (HUVEC) cells. Mechanism of action The tumstatin fragment is cleaved by matrix metalloproteinase-9 (MMP) at the alpha chain on the collagen strand. Tumstatin interacts with the αvβ3 integrin found in the apoptosis pathway. There are two activation sites on the tumstatin fragment. One is at the N-terminus and is responsible for inhibiting angiogenesis. The other is at the C-terminus end and is primarily responsible for the proapoptotic action. Tumstatin inhibits the activation of FAK (Focal Adhesion Kinase), Phosphoinositide 3-kinase (PI3-kinase), protein kinase B (PKB/Akt), and mammalian target of rapamycin (mTOR). In addition to affecting these pathways, it also prevents the dissociation of eukaryotic initiation factor 4E protein (eIF4E) from 4Ebinding protein 1. These pathways are involved in cell proliferation, so tumstatin reacting with them results in changes in the amount of cell division that occurs. =Antiangiogenesis actions= Since tumstatin has been shown to reduce angiogenesis in tumors, there is great potential to use this knowledge as treatment for cancer. Tumstatin binds to the endothelium of the tumor and is thus able to affect tumor growth. By affecting the apoptotic pathway, tumstatin inhibits the proliferation of endothelial cells. Tumstatin is a cell-specific inhibitor for protein synthesis and therefore affects angiogenesis, which occurs at the protein synthesis level. It has been shown that the efficacy of tumstatin in reducing angiogenesis in tumors increases with tumor size (tumors larger than 500 mm³). In addition to limiting the proliferation of endothelial cells, tumstatin also limits angiogenesis in melanoma cells. The 54-132 amino acid sequence of the tumstatin fragment binds both endothelial and melanoma cells but only inhibits endothelial cell proliferation which the 185-203 amino acid sequence also binds both and inhibits only melanoma proliferation. This is important in discovering the correct binding sites for different cells types and could help to make cancer therapies more cell-type specific. One study showed that mice with a genetic deletion of the αvβ3 integrin showed accelerated tumor growth and that when tumstatin was replaced into the system, the tumor growth was disrupted and the tumor shrunk. It has also been shown that tumstatin has antiangiogenic properties in prostate cancer cells (PCa). PCa was introduced onto a Matrigel and treated with tumstatin, and the formation of new blood vessels as seen in the control did not occur with tumstatin. These studies suggest that tumstatin may be a viable treatment for many types of cancer, including but not limited to melanoma and prostate cancer. Combination treatments involving tumstatin paired with another cancer- fighting drug could be extremely beneficial. One study combined treatments of tumstatin with bevacizumab, or Avastin. This was very successful in downregulating the proliferation of renal carcinoma cells in xenografts. =Proapoptotic actions= The second mechanism of action for tumstatin in combating cancer cells is to induce apoptosis. Apoptosis is induced through the same receptor as the antiangiogenic receptor, αvβ3. It has been shown to increase apoptosis in HUVEC cells as well as HeLa cells. One study has been done to determine the exact pathway used by tumstatin to induce apoptosis. This revealed that the pathway occurs within the mitochondria. The study used HepG2 human liver carcinoma cells to test this, and found that tumstatin upregulated the expression of Caspase-9, Fas, Bax, Bid, and p53 while downregulating Bcl-2. The addition of tumstatin induced the release of cytochrome c by decreasing the mitochondrial membrane potential. These results show that the proapoptotic activation pathway for tumstatin occurs through mitochondrial regulation, and can aid in determining appropriate cancer treatments. Role in other diseases Since the mechanisms of both of these pathways are not unique to cancer, tumstatin’s regulation of angiogenesis and apoptosis has potential to treat other diseases affected by these pathways as well. =Diabetes= Diabetic nephropathy as a result of diabetes mellitus is a result of persistent high blood sugar, and is characterized by a lessened globular filtration rate. The mechanism behind diabetic nephropathy is similar to that of angiogenesis, and for this reason, tumstatin may have implications in treating the disease. It was found that VEGF is one of the mediators of glomerular hypertrophy, which causes nephropathy. Since tumstatin inhibits the binding of VEGF, it inhibits diabetic nephropathy as well as resulting in decreased glomerular hypertrophy and hyperfiltration. These findings suggest that tumstatin might be used as a treatment for diabetes by regulating the angiogenesis pathways. =Asthma= In patients with asthma, treatment with tumstatin may be beneficial. Type-IV collagen is present in the basement membrane within normal lungs, and this is reduced in asthmatic patients. There are also increased levels of MMP in the lungs of asthmatics. Since tumstatin is cleaved by MMP from the collagen in the basement membrane, it has been found that there are much lower levels of tumstatin in the airways of asthmatics than in normal patients. This could account for the increased angiogenesis and hyperresponsiveness of the airways. Increasing the levels of tumstatin in the airways would lead to decreased angiogenesis and therefore eased breathing. See also *Angiogenesis *Angiogenesis inhibitor *Apoptosis *Endostatin References Angiogenesis inhibitors "
"EML4-ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. This abnormal gene fusion leads to the production of a protein (EML4-ALK) that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells. The transforming EML4-ALK fusion gene was first reported in non-small cell lung carcinoma (NSCLC) in 2007. Signs and symptoms The signs and symptoms of this lung cancer variant seem to mimic those of the underlying major cell type. Diagnosis =Classification= Most lung carcinomas containing the EML4-ALK gene fusion are adenocarcinomas. Some studies suggest that the papillary adenocarcinoma and the signet ring cell adenocarcinoma variants are more likely to carry this fused gene than other histological variants. Screening Micrograph showing an ALK positive adenocarcinoma of the lung. ALK immunostain. Screening for ALK positive lung cancer is now a standard of care in the United States and Canada. Screening can be done with immunostaining, FISH, or next-generation sequencing (NGS). Treatment Crizotinib is a targeted therapy (FDA approved in 2011), manufactured by Pfizer and marketed under the brand name Xalkori and Crizalk that targets the EML4/ALK fusion gene. Ceritinib is a second generation targeted therapy (FDA approved in 2014), manufactured by Novartis and sold under the brand name Zykadia that also targets the EML4 fusion gene, but as a second generation drug it has a smaller molecule that allows superior penetration of the Blood Brain Barrier (BBB) over Crizotinib and is more capable of protecting the Central Nervous System (CNS). Alectinib another second generation targeted therapy and was approved (for this) by Japan in 2014Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer and by US FDA in 2015.New Oral Therapy To Treat ALK-Positive Lung Cancer. Dec 2015, manufactured by Genentech and marketed under the brand name Alecensa. Brigatinib a second generation targeted therapy (FDA approved in 2017), manufactured by Takeda and is marketed under the brand name Alunbrig. Ensartinib is a second generation targeted therapy (trial drug X-396), manufactured by XCovery. Lorlatinib is a third generation targeted therapy (awaiting FDA approval under trial drug PF-6463922), manufactured by Pfizer. TPX-0005 is a new third generation targeted therapy drug trial. Prognosis Treatment with crizotinib achieves 60% response rate. However, crizotinib showed no improvement on overall survival compared to chemotherapy https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s019lbl.pdf . This may be due to the fact that there was a 70% crossover rate to crizotinib in patients treated initially with chemotherapy. Also, patients who tested negative for EML4/ALK fusion had a response rate to crizotinib of up to 35% https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110012B.pdf . Epidemiology EML4-ALK gene fusions occur almost exclusively in carcinomas arising in non- smokers. About 4% of non-small-cell lung carcinomas involve an EML4-ALK tyrosine kinase fusion gene. 4-6% of lung adenocarcinomas involve the fusion gene. EML4-ALK mutation rarely occurs in combination with K-RAS or EGFR mutations. References External links *Entrez Gene EML4 echinoderm microtubule associated protein like 4 Homo sapiens Lung cancer "